Format

Send to:

Choose Destination
See comment in PubMed Commons below
Health Aff (Millwood). 2005 Mar-Apr;24(2):483-90.

Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior.

Author information

  • 1University of Utah, Salt Lake City, USA. zick@fcs.utah.edu

Abstract

New genetic tests for adult-onset diseases raise concerns about possible adverse selection in insurance markets. To test for this behavior, we followed 148 cognitively normal people participating in a randomized clinical trial of genetic testing for Alzheimer's disease for one year after risk assessment and Apolipoprotein E (APOE) genotype disclosure. Although no significant differences were found in health, life, or disability insurance purchases, those who tested positive were 5.76 times more likely to have altered their long-term care insurance than those who did not receive APOE genotype disclosure. If genetic testing for Alzheimer's risk assessment becomes common, it could trigger adverse selection in long-term care insurance.

PMID:
15757934
[PubMed - indexed for MEDLINE]
PMCID:
PMC1761120
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk